RNN starting to roll again,

Added another 10K, don't often do that, after a 50% move.

C L

Thought, good post, they prolly have as good shot as most of the other bios..  The CEO is well regarded.

There 's a fair sized short position, and that's likely what's pushing it now.

C L

Drangles, here's what the website says on their main drug----this is not up to date:

Supinoxin™ (RX-5902)

Supinoxin – A Potential First-in-Class Inhibitor of a Unique Cancer Protein

Supinoxin (RX-5902) is an orally administered, potential first-in-class, small molecule inhibitor of a unique cancer protein – phosphorylated-p68 (P-p68) which is selectively overexpressed in cancer cells and absent in normal tissue. P-p68 is believed to increase the activity of multiple cancer related genes including, cyclin D1, c-jun and c-myc, and play a prominent role in tumor progression and metastasis. Over-expression of P-p68 has been observed in many solid tumors, including, melanoma, colon, ovarian and lung tumors.

In preclinical studies, Supinoxin has been shown to inhibit proliferation of cancer cells in over 100 different human cancer cell lines, including, breast, ovarian, colon, pancreas, and stomach cancers, and has shown potent activity in drug-resistant cancer cells. In preclinical animal models, where human cancer cells from triple negative breast cancer, ovarian, melanoma, pancreas, or renal tumors were grafted into animals, treatment with Supinoxin resulted in a significant reduction in tumor growth.

Supinoxin is currently being evaluated in a Phase I multi-center, dose-finding, open-label, single agent clinical study in patients with advanced or metastatic solid tumors.

Interim results from the Phase I clinical trial were presented at the European Cancer Congress in September 2015. The results showed that, at the dose levels tested to date, clinical evidence of single-agent activity of Supinoxin was observed in approximately 29% of patients (4/14 patients) who showed stable disease persisting from between 255 and 497 days (as of September 14, 2015.)

In addition, Supinoxin, administered orally, appeared to be safe and well tolerated with no Grade 3 or Grade 4 adverse events and only one unrelated Grade 2 adverse event. The most frequently reported drug related adverse events were mild nausea, vomiting and fatigue. Pharmacokinetic analyses of the current data show both a predictable and desirable pharmacokinetic profile for an orally-administered route of therapy.

The Phase I study of Supinoxin is currently ongoing and Rexahn anticipates commencing a Phase Ib/IIa Proof-of-Concept clinical trial in mid-2016 in patients with triple negative breast cancer and platinum resistant ovarian cancer to more comprehensively evaluate Supinoxin’s clinical activity.

Publications
Young Bok Lee et. al. Synthesis and anticancer activity of new 1-[(5 or 6-substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4- (hetero)arylpiperazine derivatives. Bioorganic & Medicinal Chemistry 2010 (18): 7966–7974.

Young Bok Lee et.al. Synthesis, anticancer activity and pharmacokinetic analysis of 1-[(substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives. Bioorganic & Medicinal Chemistry 2012 (20): 1303–1309

Antitumor activity of a new quinoxalinyl-piperazine compound. Y.B. Lee, G. Chun, D.J. Kim, C.H. Ahn, Y. D. Kong, M.K. Jeon, J.Y. Kong (2011). American Association for Cancer Research (AACR) 102nd Annual Meeting, Orlando, FL, April 02-06, 2011. Abstract No: 1371.

Mechanistic study of a new 4-(3,5-dimethoxyphenyl)-N-(7-fluoro-3-methoxyquinoxalin-2-yl)piperazine-1-carboxamide compound (RX-5902). Y.B. Lee, D.J. Kim, G.C. Kost, J. Frank, C.H. Ahn, Z.R. Liu (2013). American Association for Cancer Research (AACR) 104th Annual Meeting, Washington, D.C., April 06-10, 2013. Abstract No: 5507.

=================================

C L

Upside Potential: Analysts expectation about REXAHN PHARMACEUTICALS, INC. (RNN) stock value to reach at $3.00

 December 15, 2016 Robert Ebelling  0 Comment Rexahn Pharmaceuticals, RNN

Rexahn Pharmaceuticals, Inc.’s (RNN)’s Stock Price Trading Update:

Rexahn Pharmaceuticals, Inc.’s (RNN), a part of Healthcare sector and belongs to Biotechnology industry; ended its day with a loss of -5.82% and finalized at the price of $0.15. During its last trading session, Stock traded with the total exchanged volume of 1.72 million shares. The average volume stands around 1.25 million shares. The average numbers of shares are traded in a security per day, during the recent 3-month period. The stock has relative volume of 1.37. Relative volume is ratio between current volume and 3-month average value, intraday adjusted.

RNN Stock Price Comparison to Moving Averages:

USA based company, Rexahn Pharmaceuticals, Inc.’s (RNN)’s latest closing price was -42.81% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -16.11% and -14.21% compared with the 20 Day Moving Average.

Earnings per share Details about RNN:

EPS growth in past 5 year was 15.00%.

EPS growth in next year is estimated to reach -42.90% while EPS growth estimate for this year is set at 25.00%.

The price to sales ratio is 17.

Performance Review:

To review the RNN previous performance, look at its past history, which highlighted below:

During last 5 trades the stock sticks almost -9.45%.

During last one month it showed the change of -14.45%.

During last 3 month it remained at -35.32%.

Along with these its year to date performance is standing at -59.89%.

Important Technical Indicators:

ATR value of company was 0.01. Relative Strength Index (RSI) was 29.97. Developed J. Welles Wilder, the Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. Traditionally, and according to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

The stock volatility for week was 7.75% while for month was 7.56%.The stock, as of last close, traded 7.06% to its 52 week low and was changed -67.64% from its 52 week high. Beta factor, which measures the riskiness of the security, was observed as -0.01. RNN’s value Change from Open was at -9.00% with a Gap of 3.49%.

Analysts Mean Rating:

Analysts’ mean recommendation for Rexahn Pharmaceuticals, Inc.’s (RNN) stands at 1.50. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.

Analysts are expecting that Rexahn Pharmaceuticals, Inc. (RNN) to achieve $2.50 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $3.00 however minimum price target advised by analysts is $2.00. The Median price target for the stock is measured at $2.50.

One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 1 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 1. 0 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.

www.hotstockspoint.com/upside-potential-analysts-expectation-rexahn-pharmaceuticals-inc-rnn-stock-value-reach-3-00/

===========================

C L